Altimmune Inc ALT 深 滬
等待開盤 09-24 09:30:00 美东时间
3.19
-0.220
-6.45%
華盛通- 最 高3.425
- 今 開3.42
- 成交量 452.75万股
- 最 低 3.15
- 昨 收 3.41
- 總市值 6.21亿
- 52周最高 6.4399
- 市盈率 靜 --
- 換手率 2.33%
- 52周最低 2.56
- 委 比 -12.16%
- 總股本 1.95亿
- 歷史最高 237.30
- 量 比 0.85
- 振 幅 8.06%
- 歷史最低 1.51
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
今天 16:10
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
09-23 21:11
Marathon, Phillips 66, Clean Energy Fuels, Altimmune, Eaton Insider Shake‑Up
Insiders have been trading these 5 stocks: (($MPC)), (($PSX)), (($CLNE)), (($AL...
08-15 21:01
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
08-15 01:35
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per share from the same period last year.
08-12 19:33
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company developing pemvidutide for serious liver diseases, announced it will report its second quarter 2026 financial results on August 12, 2026. A conference call will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update. The call will be webcast live on Altimmune’s Investor Relations website, with registration available for dial-in details. A replay will ...
08-05 12:00
Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which a...
07-28 19:05
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
Altimmune's pemvidutide demonstrated statistically significant reductions in heavy drinking days (HDD) and achieved key secondary endpoints in the Phase 2 RECLAIM trial for moderate to severe alcohol use disorder (AUD). The trial showed a 2-level reduction in WHO risk drinking levels, zero HDD, and significant improvements in abstinence and PEth biomarker levels. Pemvidutide was generally well-tolerated, with a favorable safety profile. The compa...
07-28 11:00
Zacks行业展望：Indivior、Aurinia、Ironwood、Altimmune及Marker
2026年6月26日，扎克斯股票研究聚焦5只小型制药标的：Indivior制药（INDV）、Aurinia制药（AUPH）、Ironwood制药（IRWD）、...
06-26 18:07
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
